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Abstract: The PHARMODatabase Network provides a unique opportunity to gain insight in the
complete patient journey and healthcare in the Netherlands. The PHARMODatabase Network is a
population-based network of electronic healthcare databases and combines anonymous data from
different primary and secondary healthcare settings in the Netherlands. Healthcare settings include
general practitioners, out-patient and in-patient pharmacies, hospitals and clinical laboratories.
Furthermore, databases are linked with external registries such as the Cancer Registry, Pathology
Registry and Perinatal Registry. The different data sources are linked on a patient level through
probabilistic linkage based on validated algorithms. The longitudinal and ongoing nature of the
PHARMO Database Network system enables to follow up more than 10 million residents of the
Netherlands for an average of 12 years. Data collection period, catchment area and overlap between
data sources differ. Access to the PHARMODatabaseNetwork is, by governance regulations of the
data collection, restricted to researchers of the PHARMO Institute and academic affiliates. Each
data request is checked against privacy and company policies, and requires approval of the privacy
and governance board. The terms and conditions and a data application form are available on the
PHARMO website (www.pharmo.com).
Keywords: database, record linkage, pharmacoepidemiology, observational research,
electronic health record, Netherlands
Introduction
Medicines play an important role in treating many conditions and diseases.
However, in daily practice medicines do not always work and some patients are
faced within unintended side effects. Longitudinal, multidisciplinary data are
needed to study medication use and its challenges in a real-world setting. The
PHARMO Database Network was developed to study the safety and effectiveness
of medication in daily clinical practice by means of (pharmaco-)epidemiological
research with real-world data (RWD) from the Netherlands. Starting in 1990 as the
PHARMO Record Linkage System, dispensing records from out-patient pharmacies
(ie community pharmacies) were linked to hospital admission records.1 Drug
utilization could thus be linked to clinical outcomes. Over the years, the
PHARMO Database Network has been extended with data from other healthcare
providers, including general practitioners (GPs), clinical laboratories and in-patient
pharmacies, resulting in a patient-centric population-based network of electronic
healthcare record (EHR) databases that combines ongoing data collections from
primary and secondary care in the Netherlands (Table 1). The PHARMO Database
Network provides a unique opportunity to gain insight in the complete patient
journey and healthcare in the Netherlands.
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Table 1 Databases Included in the PHARMO Database Network
Database Data Source Catchment
Areaa
Data Collected Coding System
General Practitioner
(GP) Database (in-
house)
Data from electronic patient
records registered by GPs of all
patients enrolled at the GP
Subnational
(~20% of the
Dutch
population)
● Diagnoses
● Symptoms
● Laboratory test results
● Referrals to specialists
● Healthcare product/drug prescriptions
Diagnoses and symptoms:
ICPC
Drug prescriptions: WHO
ATC Classification System
Out-patient Pharmacy
Database (in-house)
Data on all GP or specialist
prescribed healthcare products
dispensed by the community
pharmacies
Subnational
(~25% of the
Dutch
population)
● Type of product
● Date
● Strength
● Dosage regimen
● Quantity
● Route of administration
● Prescriber specialty
● Costs
Dispensings:
National product classification
WHO ATC Classification
System
In-patient Pharmacy
Database (in-house)
Data on all drug dispensing from
the hospital pharmacy, given
during hospitalization
Subnational
(~10% of the
Dutch
population)
● Type of product
● Start and end date of use
● Strength
● Dosage regimen
● Route of administration
● Prescriber specialty
Dispensings: National product
classification WHO ATC
Classification System
Clinical Laboratory
Database (in-house)
Results of tests performed on
clinical specimens, requested by
GPs or specialists
Subnational
(~5% of the
Dutch
population)
● Date and time of testing
● Test result
● Unit of measurement
● Type of clinical specimen
WCIA Coding System
LOINC (partly)
Hospital Database
(external)
Data on all hospitalizations for
more than 24 hours or for
which a bed is required, out-
patient visits and high budget
impact medication. Data are
obtained from the Dutch
Hospital Data Foundation.b
Subnational
(80% of
hospitals in
the
Netherlands)
● Diagnoses
● In- and out-patient procedures
● High budget impact medication
● Admission, discharge and visit dates
Diagnoses: WHO ICD
Procedures: DHD registration
system for procedures
Medication: Dutch
classification system
Perinatal Registry
(external)
Data on pregnancies, birth and
neonatal outcomes. Data are
obtained from Perined.c
National Information on mothers, eg:
● Maternal age
● Obstetric history
● Parity
Information on pregnancies, eg:
● Mode of conception
● Mode of delivery
Information on children, eg:
● Birth weight
● Gestational age
● Apgar score
Pathology Registry
(external)
Excerpts of histological,
cytological and autopsy
examinations. Data are obtained
from PALGA.d
National ● Summary of pathology report
● PALGA diagnosis, structured along five
classification axes:
1. Topography
2. Morphology
3. Function
4. Procedure
5. Diseases
Diagnosis codes are a
combination of diagnostic
terms (localization, acquisition
technique, abnormality) and
related to the SNOMED
coding system.
(Continued)
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Study Population and Follow-Up
The longitudinal nature of the PHARMO Database
Network system enables to follow up more than 10 million
persons over the years, or about 7 million active persons
(January 1, 2018), regardless of age and gender, of a well-
defined population in the Netherlands with a follow-up of
10 to 30 years.
The databases in the PHARMO Database Network are
supplemented by linking external, national databases and
registries in order to fill gaps in the patient journey. For
example, pharmacy, GP, laboratory and hospital records
contain limited details on cancer characteristics and out-
comes. Linkages with the Netherlands Cancer Registry2
(maintained by the Netherlands Comprehensive Cancer
Organization, since 1989) and the Pathology Registry3
(maintained by the PALGA Foundation, since 1991)
were established to add detailed information on, among
other, staging and morphology and access to tissue sam-
ples. Likewise, linkage with the national Perinatal
Registry4 (maintained by Perined, since 1999) facilitates
studies on pregnancy and outcomes. Because mother-child
pairs are identified, exposure or events during pregnancy
can be studied in relation to long-term follow-up of both
mother and child.5 Permission to use these external data-
bases is requested from the database holders on a project
basis.
Study populations are created from the PHARMO
Database Network using the data sources needed to
address the study objectives. Each database had specific
limitations regarding the study population that should be
taken into consideration when selecting the study popula-
tion. In general, the population included in the PHARMO
Database Network is representative of the Dutch
population with respect to age and gender (see Figure 1).
However, the population >80 years old is relatively large
and the population <20 years old is relatively small in
PHARMO compared to the general Dutch population.6
This is most likely the result of the differences in health-
care utilization by age. In addition, data collection periods
and catchment areas vary between the databases.
Therefore, the size of the source population for any study
depends on the databases included.
Main Variables
Data are retrieved directly from the source, ie the electro-
nic medical records of the healthcare providers who agree
to collaborate with “Stichting Informatievoorziening voor
Zorg en Onderzoek” (STIZON) and contribute to the
anonymized datasets used by the PHARMO Institute for
research purposes. Healthcare providers remain owner of
the data and contribute to the PHARMO Database
Network voluntarily. Since 2012, the data is managed
and collected at least once a year by STIZON, an ISO/
IEC 27001 and NEN 7510 certified foundation, compliant
to data protection regulations. STIZON acts as a Trusted
Third Party between the data sources and users of the
anonymized data. STIZON has data processing and service
agreements with all participating healthcare providers and
acts as a processor in terms of the General Data Protection
Regulation (GDPR). STIZON collects identifiable patient
data from the contributing healthcare providers through a
technology-assisted extract, transform, load (ETL) process
that maps data from disparate sources to a common data
model.
STIZON also links the different sources on a patient
level using a combination of deterministic linkage on a
Table 1 (Continued).
Database Data Source Catchment
Areaa
Data Collected Coding System
Cancer Registry
(external)
Data on all newly diagnosed
cancer cases. Data are obtained
from the Dutch Comprehensive
Cancer Organization.e
National ● Cancer diagnosis
● Tumor staging
● Tumor site
● Morphology
● Comorbidity at diagnosis
● Initial treatment
Tumor staging: TNM-
classification
Tumor site and morphology:
WHO ICD-O
Notes: aas determined September 2016; bwww.dhd.nl; cwww.perined.nl; dwww.palga.nl; ewww.iknl.nl.
Abbreviations: ATC, Anatomical Therapeutic Chemical; DHD, Dutch Hospital Data Foundation; GP, general practitioner; ICD, International Classification of Diseases;
ICD-O, International Classification of Diseases for Oncology; ICPC, International Classification of Primary Care; LOINC, Logical Observation, Identifiers, Names and
Codes; PALGA, Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief (ie nationwide network and registry of histo- and cytopathology in the Netherlands);
SNOMED, Systematized Nomenclature of Medicine; TNM, Tumor Nodes Metastasis Classification of Malignant Tumors; WCIA, Werkgroep Coordinatie Informatie
Automatisering (ie Dutch coding system for lab tests); WHO, World Health Organization.
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unique patient identification number, when available, and
probabilistic linkage on patient characteristics.1 Validation
of the linkage against name and address information for a
sample of the patients resulted in a sensitivity and speci-
ficity of 0.98.7 The linkage is updated on a yearly basis.
After linkage, study-specific datasets can be requested by
the PHARMO Institute or academic affiliates by submit-
ting a data request accompanied by a study protocol to
STIZON. Upon approval by the Compliance Committee,
described in more detail below, the study-specific datasets
are depleted of patient identifiable information by
STIZON and made available to the PHARMO Institute
and academic affiliates for research purposes. The use of
anonymized, proportional datasets via a remote server is in
accordance with the GDPR. Records are anonymized by
replacing identifiers with randomly generated ones that
only have meaning within the dataset. While this approach
provides direct non-identifiability, pseudonymized records
may still be indirectly identifiable through probabilistic
matching between datasets with quasi-identifiers (eg postal
codes). To mitigate this issue, all identifiers that have
external relevance are removed (eg social security num-
bers are cleared), and common quasi-identifiers are aggre-
gated into categories (ie postal codes are shortened to four-
digit numbers) before the data are made available for
research purposes.
All patients registered at the contributing healthcare
providers are included, unless the patient requested to opt
out. Healthcare providers are advised to inform their
patients regarding participation in the PHARMO
Database Network and information materials are made
available by STIZON. The frequency of data collection
varies per healthcare provider but is at least on an annual
basis. Linkage of the different data sources is yearly; the
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
NL PHARMO
A
%Female
%Male
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
NL PHARMO
B
>80 years
>65-80 years
>40-65 years
>20-40 years
0-20 years
Figure 1 Sex (A) and age (B) distribution of population in the PHARMO Database Network compared to the Dutch population.
Notes: (A) dark blue: female, bright blue: male; (B) bright blue: >80 years, purple: >65–80 years, orange: >40–65 years, light blue: >20–40 years, dark blue: 0–20 years.
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lag time is about 1 year. Once the linked data are made
available to PHARMO, the quality of the data is assessed
by data acceptance tests. The contents of these yearly tests
differ per database but include quality indicators such as
level of missing data, values within a reasonable range and
appropriate coding used.
The type of data collected per data source is described
in Table 1. The GP Database contains detailed information
on patient characteristics, symptoms, diagnosis, prescribed
medication and requested laboratory tests, including test
results. The GP is the gatekeeper of the Dutch healthcare
system and all patients, regardless of age or insurance, are
uniquely registered by a single GP. Access to secondary
care is only through referral by the GP. Due to the central
position of the GP in the healthcare system, they play a
key role in the patient journey. The GPs manage specific
care programs for chronic diseases such as type 2 diabetes
mellitus, chronic obstructive pulmonary disease (COPD)/
asthma and cardiovascular risk management. In these pro-
grams, patients are monitored and treated in accordance
with predefined, nationwide implemented standardized
rules (eg specific tests and frequency of testing). GPs are
reimbursed based on their compliance with these prede-
fined rules. In order to support GPs with being compliant
to these care programs, feedback information is provided
to the GP based on the data collected by STIZON. As a
result of this feedback loop, the disease cohorts based on
these care programs are validated and contain frequently
monitored patients with a very high level of detail
available.
The Out-patient Pharmacy Database and the In-patient
Pharmacy Database include information on the type of
medication dispensed, including Anatomical Therapeutic
Chemical (ATC) code and brand names, dosage, duration
of dispensing and information on the prescriber. The Out-
patient Pharmacy Database includes all medication dis-
pensed in community- and hospital-based out-patient phar-
macies, regardless of insurance, employment status,
prescriber, age or gender. The In-patient Pharmacy
Database includes all medication dispensed during a hos-
pitalization. The Out-patient Pharmacy and In-patient
Pharmacy Databases do not include information on the
indication of treatment, due to local laws and regulations.
Linkage with another database, such as the GP Database is
needed to infer the indication, by concurrent diagnoses.
The Clinical Laboratory Database includes the type of
laboratory test, by whom the test was requested and the
results of the laboratory tests.
The Hospital Database comprises datasets containing
data on hospital admissions, ambulatory consultations and
high budget impact medication. The datasets on hospital
admissions and ambulatory consultations include informa-
tion on admission, discharge and consultation dates, pri-
mary and secondary diagnoses and procedures. The dataset
on high budget impact medication includes information on
type of drug dispensed, date of dispensing, prescriber and
indication of use. Hospital data are maintained and pro-
cessed by the Dutch Hospital Data foundation (DHD),
STIZON is authorized by the individual hospitals to obtain
this data from the DHD and use it for research purposes.
Each hospital is responsible for data collection according
to the common data model developed by the DHD in
collaboration with the Dutch hospital associations.8
As with any database, identification of medical events
is limited to data that are captured as part of the medical
records or other linked data sources in daily practice.
These data are not primarily collected for research pur-
poses and rely on appropriate diagnostic coding to detect
these events. Furthermore, only the complications that
require medical attention are included in the PHARMO
Database Network, which mostly concerns the more
severe and acute events.
Through the collaboration with STIZON, in its role as
Trusted Third Party, it is possible to go back to the health-
care provider for validation or extension of the retrospec-
tively collected data by chart review or additional data
collection.
Research Examples
The use of the study-specific datasets from the PHARMO
Database Network is controlled by an independent privacy
and governance board, the Compliance Committee. The
Compliance Committee consists of representatives of all
different healthcare providers and a separate privacy
expert, including the GDPR data protection officer of
STIZON. All studies require permission of the
Compliance Committee and its decisions are based on
the applicable Dutch and European legislations, including
the Medical Treatment Contracts Act (WGBO). The
majority of studies using the anonymized data from the
PHARMO Database Network are not subject to ethics
review according to the Medical Research Involving
Human Subjects Act (WMO). In the cases where ethics
approval is required, the study protocol is submitted to an
accredited medical research ethics committee in the
Netherlands for review.
Dovepress Kuiper et al
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Data from the PHARMO Database Network have been
used in over 1000 studies and 500 publications in peer-
reviewed journals, both national and international. These
studies and publications cover all major therapeutic areas,
including oncology and metabolic, cardiovascular and
respiratory diseases. Research topics include drug safety
(including authority driven post-authorization safety stu-
dies), healthcare resource utilization, relative effective-
ness, drug utilization, disease surveillance, burden of
illness and treatment patterns.
Besides studies focusing on the Netherlands, the
PHARMO Institute coordinates and participates in inter-
national database studies. In these studies, PHARMO col-
laborates with other expertise centers to benefit from each
partner’s local expertise of the data and the healthcare
system; the context of the data puts the study results in
perspective. The majority of the international database
studies are registered in the ENCePP register.9 In the
context of a multi-country study, PHARMO can share
data on an aggregated level.
The list of publications based on the PHARMO
Database Network can be obtained online at http://www.
pharmo.nl/. Three examples of publications showing the
research possibilities with data from the PHARMO
Database Network are described below.
For a study on benign prostatic hyperplasia (BPH) a
combination of three databases was used.10 The objective
of the study was to compare the rates of BPH-related
prostate surgery and acute urinary retention between
dutasteride and finasteride alone or in combination with
an alpha-adrenoreceptor antagonist. The Out-patient
Pharmacy Database was used to identify the study popula-
tion, ie men aged 50 years or older who were treated with
dutasteride or finasteride. The Hospitalization Database
was used to determine study outcomes, ie BPH-related
prostate surgery and acute urinary retention. The GP
Database was used to determine complaints and covari-
ates, eg comorbidities and number of GP visits. The study
showed that the risk of BPH-related prostate surgery was
significantly lower among men using dutasteride than
among men using finasteride.
Another publication described musculoskeletal hospital
admissions and surgical procedure rates among patients
treated for rheumatoid arthritis (RA) during the introduc-
tion of biological disease-modifying anti-rheumatic drugs
(DMARDs) in the Netherlands.11 The rates were compared
with population references. RA patients were identified by
dispensing of any relevant DMARD and absence of
alternative indications. Relevant DMARDs were based
on Dutch treatment guidelines for RA and were categor-
ized as conventional or biological DMARD. These selec-
tion criteria may have resulted in an overestimation of
patients with RA due to the limited specificity in the
group without an admission for RA. Patients with an
admission for RA most likely represent patients with
more advanced disease. This study showed that the rates
of musculoskeletal surgical procedures among patients
treated for RA decreased between 1999 and 2012. The
largest reduction occurred during the period when bio-
DMARDs were introduced. However, the surgical proce-
dure rate remained more than twice as high for patients
with RA as compared to reference subjects and was almost
four times higher among patients receiving bio-DMARDs.
It was hypothesized that these increased rates are most
likely explained by the fact that bio-DMARDs are indi-
cated for patients with more advanced disease. Severity of
disease indicators could not be retrieved from the data-
bases included in this study.
In a study on the association between expression of
HLA class I antigen, aspirin use and survival in patients
diagnosed with colon cancer, tissue samples available
through the PALGA Foundation were used in combination
with data from the PHARMO Database Network.12
Information on diagnosis and medication use were
retrieved from the PHARMO Database Network and was
linked to the HLA class I antigen results as determined in
the tissue samples retrieved through the PALGA
Foundation. By retrieving data on medication use from
dispensing records rather than patients, recall bias was
avoided. The study showed that in tumors expressing
HLA class I antigen, aspirin use after colon cancer diag-
nosis was associated with improved survival. Upon con-
firmation in other data sets, the results of this study could
impact timing and dose of aspirin in clinical practice.
Data Access and Funding
Access to the PHARMO Database Network is, by govern-
ance regulations of the data collection, restricted to
researchers of the PHARMO Institute and academic affili-
ates. Academic affiliates from universities or research
institutes can apply for access to the data of the
PHARMO Database Network for scientific studies. This
endeavor is in line with the policy and mission of the
PHARMO Institute to contribute to a better understanding
of the use, safety, effectiveness and cost of pharmaceuti-
cals as used in real-life. The application form can be found
Kuiper et al Dovepress
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on the PHARMO website (www.pharmo.com) and should
be submitted together with a study protocol. Applications
are checked against the policies that apply for use of data
from the PHARMO Database Network and as agreed upon
with the contributing healthcare providers. Funding for
academic research is not provided by the PHARMO
Institute and should be obtained by the researcher taking
into account the data access fees for use of the data. Upon
approval of the data application by the CC, researchers are
provided access to the data at the PHARMO Institute
offices. In 2019, almost one-third of all projects using
data from the PHARMO Database Network were per-
formed by academic affiliates. The remaining studies
were mainly commissioned by pharmaceutical companies
(43%) and contract research organizations (18%). Other
funding sources include the European Medicines Agency
(EMA) and funding programs, eg FP6/7.
Conclusion
The PHARMO Database Network provides a unique
opportunity to conduct studies on the safety and effective-
ness of medication use in the Netherlands. The PHARMO
Database Network covers a well-defined population-based
sample of patients with detailed information from multiple
healthcare settings. The longitudinal nature of the data
allows for long-term follow-up of patients and surveillance
of long-term outcomes, beyond the scope of most prospec-
tive studies.
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